Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Antianginal Drugs: Nitrates and β-Blockers

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Critical limits for early detection of glaucoma, the Uppsala Glaucoma Detection Study (UGDS).

International ophthalmology·2026

Same author

A novel suprachoroidal microinvasive glaucoma implant: in vivo biocompatibility and biointegration.

BMC biomedical engineering·2020

Same author

Gray Optic Disc Crescent: Evaluation of Anatomic Correlate by Spectral-Domain OCT.

Ophthalmology. Glaucoma·2020

Same author

Secretory proteostasis of the retinal pigmented epithelium: Impairment links to age-related macular degeneration.

Progress in retinal and eye research·2020

Same author

Thrombospondin-2 is up-regulated by TGFβ2 and increases fibronectin expression in human trabecular meshwork cells.

Experimental eye research·2019

Same author

Proteomic analysis of the aqueous humour in eyes with pseudoexfoliation syndrome.

The British journal of ophthalmology·2019

Search research articles

Related Experiment Video

Updated: Jun 27, 2026

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

Side effects associated with prostaglandin analog therapy.

Albert Alm¹, Ian Grierson, M Bruce Shields

¹Department of Neuroscience, Ophthalmology, University Hospital, Uppsala, Sweden.

Survey of Ophthalmology

|December 17, 2008

Summary

Topical prostaglandin analogs are effective glaucoma treatments with generally good systemic safety. However, they can cause common cosmetic ocular side effects and rarer, potentially sight-threatening ones.

Related Experiment Videos

Last Updated: Jun 27, 2026

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

Area of Science:

Ophthalmology
Pharmacology

Background:

Topical prostaglandin analogs are first-line therapy for glaucoma management.
These medications offer an excellent systemic safety profile.
Ocular side effects are associated with their use.

Purpose of the Study:

To review the ocular side effects of topical prostaglandin analogs.
To differentiate between common and rare adverse events.
To compare the side effect profiles of different prostaglandin analogs.

Main Methods:

Literature review focusing on side effects of prostaglandin analogs.
Analysis of reported ocular adverse events.
Comparison of side effect incidence and severity.

Main Results:

Common ocular side effects include conjunctival hyperemia, eyelash changes, iris darkening, and skin pigmentation.
Rarer, potentially sight-threatening side effects include iris cysts, cystoid macular edema, anterior uveitis, and herpes simplex keratitis reactivation.
Latanoprost shows less conjunctival hyperemia compared to other analogs, but overall side effect profiles are similar.

Conclusions:

Topical prostaglandin analogs have a favorable safety profile but require monitoring for ocular side effects.
Most side effects are cosmetic, but vigilance for rarer, serious events is crucial.
Available prostaglandin analogs have comparable side effect profiles, with minor differences.